



SHL/SEC/2021

October 27, 2021

The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort
Mumbai – 400 001.

The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India

Company Code: 537253

Dear Sir,

Sub. : Outcome of the 246th Board Meeting held on 27.10.2021.

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Wednesday, October 27, 2021, the meeting was started at 03:15p.m., and concluded at 05:28p.m. 3

1. Approved Unaudited Financial Results (Standalone & consolidated) for the 02nd quarter/1st half year ended September 30, 2021 of the Financial Year 2021-22 and noted Limited Review Report on the same (Copy enclosed as Annexure-1).
2. Expansion of Installed Production Capacity of Empty Hard Capsule shell from 13.80 billion to 15.00 billion (appox) p.a. in the financial year 2021-22, Sellable output has been obtained from current quarter as on date.

You are requested to take the above information in your record and oblige us.

Thanking you,
Yours sincerely,
for Sunil Healthcare Limited

Santosh Kumar Sharma
Company Secretary
FCS-6817
Date: 27.10.2021
Place: New Delhi
Encl.: a/a

Sunil Healthcare Limited

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049

T: +91 11 49435555/00 F: +91 11 43850087 E-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com

CIN No.: L24302DL1973PLC189662

**SUNIL HEALTHCARE LIMITED**

Registered Office

38E/252-A, Vijay Tower, Shahpurjat

New Delhi-110049

Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com

CIN : L24302DL1973PLC189662

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2021

Rs. in Lakhs

		Standalone					Year Ended Standalone	Consolidated					Year Ended Consolidated
		Quarter ended		Half Year Ended				Quarter ended		Half Year Ended			
		30th September 2021	30th June 2021	30th September 2020	30th September 2021	30th September 2020		31st March 2021	30th September 2021	30th June 2021	30th September 2020	30th September 2021	
Particulars		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	2,806.43	2,617.99	2,267.24	5,424.42	4,367.42	8,963.11	2,918.67	2,650.78	2,285.04	5,569.45	4,448.44	9,029.19
2	Other Income	51.78	18.59	52.84	70.37	67.28	562.07	42.59	24.41	66.10	67.00	79.12	557.89
3	Total Income (1+2)	2,858.21	2,636.58	2,320.08	5,494.79	4,434.70	9,525.18	2,961.26	2,675.19	2,351.14	5,636.45	4,527.56	9,587.08
4	Expenses												
	a) Cost of Materials consumed	997.78	1,002.14	790.10	1,999.92	1,439.64	3,261.55	997.78	1,002.14	790.10	1,999.92	1,439.64	3,261.55
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	246.45	153.60	130.09	400.05	467.79	1,011.86	332.65	161.57	122.57	494.22	474.21	1,008.73
	c) Employees benefit expenses	337.79	349.73	311.79	687.52	620.67	1,229.52	337.79	349.73	311.79	687.52	620.67	1,229.52
	d) Finance Costs	91.06	106.46	144.25	197.52	290.82	530.85	91.06	106.46	144.25	197.52	290.82	530.85
	e) Depreciation and amortisation	157.59	155.34	154.04	312.93	305.68	611.30	157.63	155.38	154.06	313.01	305.71	611.35
	f) Other Expenses	969.10	832.22	782.65	1,801.32	1,301.30	2,845.16	1,020.26	868.10	812.63	1,888.36	1,398.67	3,000.40
	Total Expenses	2,799.77	2,599.49	2,312.92	5,399.26	4,425.90	9,490.24	2,937.17	2,643.38	2,335.40	5,580.55	4,529.72	9,642.40
5	Profit before tax (3-4)	58.44	37.09	7.16	95.53	8.80	34.94	24.09	31.81	15.74	55.90	(2.16)	(55.32)
6	Tax Expenses (Net)	18.79	9.59	0.91	28.38	2.49	7.41	20.12	10.97	1.74	31.09	3.81	8.47
	a) Current Tax	-	-	-	-	-	-	-	-	-	-	-	-
	i)-Current Tax	(16.76)	33.35	-	16.59	-	-	(16.06)	34.00	0.83	17.94	1.32	0.23
	ii)-Tax for Earlier Period	-	-	-	-	-	4.64	0.63	0.73	-	1.36	-	5.47
	b) Deferred Tax Charged/(Credit)	35.55	(23.76)	0.91	11.79	2.49	2.77	35.55	(23.76)	0.91	11.79	2.49	2.77
7	Profit/(loss) after tax	39.65	27.50	6.25	67.15	6.31	27.53	3.97	20.84	14.00	24.81	(5.97)	(63.79)
8	Other Comprehensive Income (OCI)	-	-	-	-	-	1.98	2.00	(6.24)	1.20	(4.24)	(0.51)	-
	a) Items that will not be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	1.98	-	-	-	-	-	1.98
	b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	2.00	(6.24)	1.20	(4.24)	(0.51)	(26.27)
9	Total Comprehensive Income	39.65	27.50	6.25	67.15	6.31	29.51	5.97	14.60	15.20	20.57	(6.48)	(88.08)
10	Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
11	Other Equity				3,848.93	3,758.58	3,781.78				3,366.73	3,427.87	3,346.25
12	Earning per share of Rs.10/- each(not annualised)												
	(a) Basic (Rs.)	0.39	0.27	0.06	0.65	0.06	0.27	0.04	0.20	0.14	0.24	(0.06)	(0.62)
	(b) Diluted (Rs.)	0.39	0.27	0.06	0.65	0.06	0.27	0.04	0.20	0.14	0.24	(0.06)	(0.62)
	Earning per share of Rs.10/- each(not annualised)												
	(a) Basic (Rs.)	0.39	0.27	0.06	0.65	0.06	0.27	0.04	0.20	0.14	0.24	(0.06)	(0.62)
	(b) Diluted (Rs.)	0.39	0.27	0.06	0.65	0.06	0.27	0.04	0.20	0.14	0.24	(0.06)	(0.62)

Statement of Assets and Liabilities

2	Particulars	Standalone		Consolidated	
		As at	As at	As at	As at
		30th Sep. 2021	31st March 2021	30th Sep. 2021	31st March 2021
		Un-audited	Audited	Un-audited	Audited
A	ASSETS				
1	Non Current Assets				
(a)	Fixed Assets				
	(i) Property, Plant and Equipment	5,517.68	5,477.09	5,518.13	5,477.21
	(ii) Capital Work-in-Progress	1.68	0.69	1.68	0.69
	(iii) Right of Use Assets	1,470.93	1,483.00	1,470.93	1,483.00
	(iv) Other Intangible Assets	19.06	20.08	19.06	20.08
(b)	Financial Assets				
	(i) Investment	116.08	120.34	103.07	107.33
	(ii) Loans	85.85	92.86	85.85	92.86
(c)	Other non-current Assets	76.80	24.25	76.80	24.25
2	Current Assets				
(a)	Inventories	795.75	1,126.27	957.80	1,372.88
(b)	Financial Assets				
	(i) Loan	29.70	29.40	-	-
	(ii) Trade Receivables	2,455.78	2,778.52	2,107.51	2,343.11
	(iii) Cash and Cash Equivalents	6.52	4.81	20.99	55.20
	(iv) Other Bank Balances	399.48	772.62	399.48	772.62
	(v) Other Financial Assets	80.77	162.28	35.64	36.74
(c)	Current Tax Assets	0.65	16.27		16.40
(d)	Other Current Assets	147.85	247.96	154.70	254.06
	TOTAL ASEESTS	11,204.58	12,356.44	10,951.64	12,056.43
B	EQUITY AND LIABILITIES				
1	Equity				
	(a) Equity Share Capital	1,025.48	1,025.48	1,025.48	1,025.48
	(b) Other Equity	3,848.93	3,781.78	3,366.73	3,346.25
2	Non Current Liabilities				
	(a) Financial Liabilities-				
	(i) Borrowings	1,055.48	1,569.60	1,055.48	1,569.60
	(ii) Lease Liability	32.14	44.19	32.14	44.19
	(b) Provisions	206.13	210.54	206.13	210.54
	(c) Deferred Tax Liabilities (Net)	566.84	555.04	566.84	555.04
3	Current Liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	2,870.00	3,343.62	2,870.00	3,343.62
	(ii) Trade Payables				
	Total Outstanding dues of Micro enterprises and small enterprises	192.84	97.29	192.84	97.29
	Total Outstanding dues of Creditors other than Micro enterprises and small enterprises	606.98	1,170.09	626.90	1,183.07
	(iii) Lease Liabilities	25.56	24.63	25.56	24.63
	(iv) Other Financial Liabilities	58.82	57.55	58.82	57.55
	(b) Other Current Liabilities	621.99	383.24	831.08	505.78
	(c) Provisions	93.39	93.39	93.39	93.39
	(d) Current tax liabilities(Net)	-	-	0.25	-
	TOTAL - EQUITY AND LIABILITIES	11,204.58	12,356.44	10,951.64	12,056.43
		-	-	-	-

Cash Flow Statement

3	Particulars	Cash Flow Statement			
		Standalone		Consolidated	
		For the Half year ended 30th Sep 2021	For the Half year ended 30th Sep 2020	For the Half year ended 30th Sep 2021	For the Half year ended 30th Sep 2020
		Un-audited	Un-audited	Un-audited	Un-audited
A. Cash Flow From Operating Activities					
Profit before Tax from continued business		95.53	8.80	55.90	(2.16)
Profit before Tax from discontinued business			-		-
Adjustment for :					
Finance Costs		197.52	290.82	197.52	290.82
Depreciation and Amortization Expenses		312.93	305.68	313.01	305.71
Sundry balances written back		69.57		69.57	
(Profit)/Loss on Sales/Discarded of Property ,Plant and Equipment		0.47	3.84	0.47	3.84
Interest Income		(11.67)	(13.02)	(11.49)	(13.02)
Fair valuation of Investments measured at FVTPL		(1.71)	(0.59)	(1.71)	(0.59)
Profit on sale of Investments measured at FVTPL		0.01		0.01	
Baddebts/Provision for loss allowances		306.27	-	306.27	-
Liabilities/ Provisions no longer required written back		-	1.97	(0.01)	(4.04)
Unrealised (gain)/loss foreign currency transactions and translation/FCTR		(9.37)	(2.01)	(13.32)	(5.89)
Operating profit before working capital changes		959.55	595.49	916.22	574.67
Changes in working Capital:					
(Increase)/Decrease in Inventories		330.52	497.65	415.07	503.08
(Increase)/Decrease in Trade and other Receivables		69.29	(81.20)	51.81	(255.44)
Increase /(Decrease) in Trade and other payable		(233.44)	(768.60)	(209.08)	(574.72)
Cash generation from Operation		1,125.92	243.34	1,174.02	247.59
Payment/refund of Direct Taxes		(0.97)	(1.48)	(2.65)	(2.80)
Net Cash generated/ (used) - Operating Activities		1,124.95	241.86	1,171.37	244.79
B. Cash Flow from Investing Activities					
Purchase of Property, Plant and Equipment & Intangible Assets		(405.20)	(279.15)	(405.20)	(279.15)
Sale of Property, Plant and Equipment		0.31	1.88	0.31	1.88
Sale of Mutual Funds		5.96		5.96	
Movement in Receivable from subsidiaries		82.34	-		
Movement in Term Deposits		373.14	(7.42)	373.14	(7.42)
Interest Received		6.61	14.79	6.61	14.79
Net Cash Generated/ (Used) - Investing Activities		63.16	(269.90)	(19.18)	(269.90)
C. Cash Flow from Financing Activities					
Receipts from Non Current Borrowings		-	131.82	-	131.82
Repayment of Non Current Borrowings		(251.98)	(133.52)	(251.98)	(133.52)
Loan repaid to Director		(237.00)	-	(237.00)	-
Receipts/(Repayment) of Short-term Borrowings (Net)		(506.44)	785.85	(506.44)	785.85
Payment of lease liability		(11.12)	(7.85)	(11.12)	(7.85)
Finance Cost Paid		(179.86)	(141.82)	(179.86)	(141.82)
Net Cash Generated/ (Used) - Financing Activities		(1,186.40)	634.48	(1,186.40)	634.48
Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)		1.71	606.44	(34.21)	609.37
Add : Opening Cash and Cash Equivalents		4.81	116.48	55.20	134.05
Closing Cash and Cash Equivalents		6.52	722.92	20.99	743.42
		(0.00)		(0.00)	

4 COVID - 19 pandemic has caused serious disruption on the global economic and business environment. There is a huge uncertainty with regard to its impact which cannot be reasonably determined at this stage. However, the Company has evaluated and considered to the extent possible the likely impact that may arise from COVID-19 pandemic as well as all event and circumstances upto the date of approval of these Financial results on the carrying value of its assets and liabilities as on 30.09.2021. Based on the current indicators of future economic conditions, the Company estimates to recover the carrying amount of these assets and to discharge its obligation as adequate liquidity is available. These estimates are subject to uncertainty and may be affected by the severity and duration of the pandemic. The Company is continuously monitoring any material changes in future economic conditions.

5 As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.

6 The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to conform current period classifications.

7 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on October 27, 2021 .

JKVS & CO.

Chartered Accountants

Review Report on unaudited standalone quarterly and half yearly financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and half year ended September 30, 2021. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: October 27, 2021



For JKVS & Co.
Chartered Accountants
Firm Registration No. 318086E


Sajal Goyal
Partner

Membership No. 523903
UDIN: 21523903AAAAEB2925

JKVS & CO.

Chartered Accountants

Independent Auditor's Review Report on consolidated unaudited quarterly and half yearly financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Sunil Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2021, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities
 - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
 - b. Sunil Healthcare North America LLC (Incorporated in USA)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The consolidated unaudited financial results include the interim financial results of two foreign subsidiaries whose financial statements are not required to review according to the law of respective countries and whose financial results reflect total assets of Rs. 706.86 Lakhs as at September 30, 2021 and total revenue from operation of Rs. 176.79 Lakhs and Rs. 263.54 Lakhs, Loss after tax of Rs. (6.93) Lakhs and Rs. 6.48 Lakhs and total comprehensive income of Rs. (4.49) Lakhs and Rs. (10.73) Lakhs for the quarter and half year ended September 30, 2021 respectively, and net cash outflow of Rs. 35.91 Lakhs for the half year ended September 30, 2021 as considered in the Statement. According to the information and explanations given to us by the management, these Interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Place: New Delhi
Date : October 27, 2021



For JKVS & Co.
Chartered Accountants
Firm Registration No. 318086E


Sajal Goyal
Partner

Membership No. 523903
UDIN: 21523903AAAAEC6453